Results for: Starboard Value

Activist investor Starboard Value has sharply criticized Pfizer, accusing the pharmaceutical giant of failing to deliver on its promises of innovation and growth. Starboard argues that Pfizer’s leadership has not capitalized on the momentum following the COVID-19 pandemic, resulting in underperformance in research and development (R&D) and mergers and acquisitions (M&A). The investor highlights the company’s missed targets, inflated acquisitions, and lagging returns on investments, calling for the board to hold management accountable.

Kenvue Inc. (KVUE) shares jumped on Monday following reports that activist investor Starboard Value has acquired a significant stake in the company. Starboard is pushing for changes to boost the consumer-products company’s share price, citing underperformance compared to competitors. The move could lead to a sale of Kenvue’s skin, healthcare, and beauty division, according to industry analysts.

Starboard Value, a prominent activist investor, has reportedly acquired a significant stake in Kenvue Inc., the company behind popular consumer brands like Tylenol and Listerine. The move signals potential changes for Kenvue, which has faced stock underperformance since its spin-off from Johnson & Johnson last year. Starboard’s CEO, Jeff Smith, is expected to outline his plans for Kenvue at an upcoming activist investing conference.

Former Pfizer CEO Ian Read and ex-CFO Frank D’Amelio have publicly thrown their support behind current CEO Albert Bourla, distancing themselves from the activist campaign led by Starboard Value. Their statement comes as Starboard, known for its aggressive tactics, has built a significant stake in Pfizer, prompting a showdown with the company’s board.

Pfizer, facing declining share price and strategic criticism, is under pressure from activist investor Starboard Value, which has acquired a $1 billion stake in the company. Starboard is pushing for a more focused development strategy and deeper cost cuts, aiming to turn around the pharmaceutical giant’s fortunes.

News Corporation (NWS) is facing pressure from its largest shareholder, Starboard Value LP, to eliminate its dual-class share structure. Starboard argues that this structure, which gives more voting power to the founder’s heirs, is not in the best interests of shareholders and is detrimental to corporate governance. The move comes as News Corp’s stock has struggled to keep up with its perceived value.